Skip to main content

Wilson's Disease clinical trials at UC Health

3 in progress, 1 open to eligible people

Showing trials for
  • A Study of Experimental ALXN1840 in Participants With Wilson Disease

    open to eligible people ages 18 years and up

    The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at least 1 year with standard of care (that is, trientine, penicillamine, or zinc). In the Treatment Period, efficacy and safety of ALXN1840 will be assessed at Week 48.

    at UC Davis

  • A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

    Sorry, not currently recruiting here

    The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.

    at UC Davis

  • Effectiveness and Safety of Experimental ALXN1840 Versus Standard of Care for Wilson Disease (copper buildup)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in WD patients aged 12 and older.

    at UCLA

Last updated: